Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.6310
Nov 20 • 3:59 PM ET Dollar change+0.0173 Percentage change(2.82%)
Aftermarket Close
0.6310
Aftermarket • 4:15 PM ET Dollar change0.0000 Percentage change(0.00%)
Nov 19, 4:10 PMStandard BioTools stockholders approved all proposals for its Treeline merger and Mass Cytometry business sale.
Index
-
Market Cap
249.11M
Enterprise Value
-185.17M
Income
-69.20M
Sales
84.43M
Book/sh
1.41
Cash/sh
1.17
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
389
IPO
Feb 10, 2011
P/E
-
Forward P/E
-
PEG
-
P/S
2.95
P/B
0.45
P/C
0.54
P/FCF
-
EV/EBITDA
-
EV/Sales
-2.19
Quick Ratio
9.40
Current Ratio
9.75
Debt/Eq
0.05
LT Debt/Eq
0.04
Option/Short
Yes / Yes
EPS (ttm)
-0.18
EPS next Y
-0.16
EPS next Q
-0.02
EPS this Y
33.33%
EPS next Y
-60.00%
EPS next 5Y
-
EPS past 3/5Y
56.76% 23.22%
Sales past 3/5Y
-4.49% -9.19%
EPS Y/Y TTM
47.75%
Sales Y/Y TTM
-34.46%
EPS Q/Q
53.75%
Sales Q/Q
-0.85%
Insider Own
4.08%
Insider Trans
0.47%
Inst Own
73.28%
Inst Trans
-2.87%
ROA
-6.34%
ROE
-7.79%
ROIC
-12.00%
Gross Margin
50.82%
Oper. Margin
-55.98%
Profit Margin
-81.96%
SMA20
1.01%
SMA50
-5.52%
SMA200
-26.01%
Trades
Shs Outstand
394.67M
Shs Float
378.68M
52W High
1.72 -63.31%
52W Low
0.39 61.79%
Volatility
23.92% 10.38%
ATR (14)
0.06
RSI (14)
49.31
Beta
1.45
Rel Volume
2.36
Avg Volume
1.19M
Volume
2,808,212
Perf Week
-10.80%
Perf Month
-0.72%
Perf Quarter
-2.92%
Perf Half Y
-38.74%
Perf YTD
-50.70%
Perf Year
-50.70%
Perf 3Y
-72.20%
Perf 5Y
-85.95%
Perf 10Y
-89.69%
Prev Close
0.61
Price
0.63
Change %
2.82%
Consensus
Hold
Avg. Price Target
$1.35
Implied Upside
+113.9%
Analysts3incl. previous ratings
Rating Distribution1 Buy · 2 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 13, 2025Downgrade
TD logoTTD Cowen
Buy → Hold$1.55+145.6%
Feb 27, 2025Downgrade
KEY logoKKeyBanc Capital Markets
Overweight → Sector Weight
Apr 16, 2024Initiated
TD logoTTD Cowen
Buy$3.50+454.7%
Apr 04, 2024Initiated
JEF logoJJefferies
Buy$3.25+415.1%
Jul 12, 2023Initiated
KEY logoKKeyBanc Capital Markets
Overweight$4+533.9%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carey Thomas D.DirectorNov 05 '26Buy0.6375,00046,898419,456Nov 05 05:36 PM
Egholm MichaelPresident & CEOApr 06 '26Option Exercise0.00196,51306,790,596Apr 08 09:55 PM
Kim Hanjoon AlexChief Financial OfficerApr 06 '26Option Exercise0.0070,18302,800,702Apr 08 09:55 PM
Casdin Partners Master Fund, LDirectorDec 04 '25Buy1.45150,000217,02072,100,000Dec 04 08:59 PM
Casdin Partners Master Fund, LDirectorDec 02 '25Buy1.42125,000177,51271,875,000Dec 04 08:59 PM
Casdin Partners Master Fund, LDirectorDec 03 '25Buy1.4475,000108,03771,950,000Dec 04 08:59 PM
Casdin Partners Master Fund, LDirectorNov 25 '25Buy1.307,550,0009,838,40571,750,000Nov 26 04:58 PM
Casdin Partners Master Fund, LDirectorNov 24 '25Buy1.43150,000214,87564,200,000Nov 26 04:58 PM
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in Boston, MA.
PresidentDr. Michael Egholm Ph.D.
Chief Financial OfficerMr. Hanjoon Kim
Senior VP & Chief Business OfficerMr. Sean Mackay
VP & Chief Accounting OfficerMr. Jonathan Mickelsen
Vice President of Investor RelationsJohn Graziano